Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18102338 | 0.77 | TSHR (0.64) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL22380663 | 0.77 | TSHR (0.64) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL99049 | 0.77 | TSHR (0.64) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL3080998 | 0.74 | PSMD14 (0.77) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL840077 | 0.74 | PSMD14 (0.44) | PSMD14TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL21917153 | 0.70 | — | — | |
| SCHEMBL20669715 | 0.70 | TSHR (0.46) | PSMD14TSHRHSD11B1 | |
| SCHEMBL4969852 | 0.67 | MAPT (0.51) | TSHRHSD11B1ALDH1A1HPGD | |
| SCHEMBL13547513 | 0.65 | — | — | |
| SCHEMBL22861645 | 0.64 | PSMD14 (0.38) | PSMD14TSHRHSD11B1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20210002296-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | PSMD14 1056/4885TSHR 2599/4885HSD11B1 3318/4885 |
| US-20210002296-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | PSMD14 14/4885TSHR 3432/4885HSD11B1 3414/4885 |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | PSMD14 1056/4885TSHR 2599/4885HSD11B1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.